

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
18 July 2024 (18.07.2024)



(10) International Publication Number
WO 2024/151638 A3

(51) International Patent Classification:

A61K 31/395 (2006.01) A61K 31/255 (2006.01)
A61K 31/4162 (2006.01) A61K 31/33 (2006.01)

(21) International Application Number:

PCT/US2024/010888

(22) International Filing Date:

09 January 2024 (09.01.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/479,292 10 January 2023 (10.01.2023) US
63/516,701 31 July 2023 (31.07.2023) US

(71) Applicant: **COGENT BIOSCIENCES, INC.** [US/US];
275 Wyman Street, 3rd Floor, Waltham, Massachusetts
02451 (US).

(72) Inventors: **FELL, Jay Bradford**; c/o Cogent Biosciences,
Inc., 4840 Pearl E Circle, Suite 100, Boulder, Colorado
80301 (US). **ROBINSON, John E.**; c/o Cogent Bio-
sciences, Inc., 4840 Pearl E Circle, Suite 100, Boulder, Col-
orado 80301 (US). **FISCHER, John P.**; c/o Cogent Bio-
sciences, Inc., 4840 Pearl E Circle, Suite 100, Boulder,
Colorado 80301 (US). **VINE, Logan E.**; c/o Cogent Bio-
sciences, Inc., 4840 Pearl E Circle, Suite 100, Boulder, Col-
orado 80301 (US). **RODRIGUEZ, Martha E.**; c/o Cogent
Biosciences, Inc., 4840 Pearl E Circle, Suite 100, Boul-
der, Colorado 80301 (US). **FULTON, Jennifer**; c/o Cogent
Biosciences, Inc., 4840 Pearl E Circle, Suite 100, Boulder,
Colorado 80301 (US). **BETTENDORF, Tanna**; c/o Co-
gent Biosciences, Inc., 4840 Pearl E Circle, Suite 100, Boul-
der, Colorado 80301 (US). **NEWHOUSE, Bradley J.**; c/
o Cogent Biosciences, Inc., 4840 Pearl E Circle, Suite 100,
Boulder, Colorado 80301 (US). **RIEGER, Robert A.**; c/o
Cogent Biosciences, Inc., 4840 Pearl E Circle, Suite 100,
Boulder, Colorado 80301 (US). **MALINKY, Cori A.**; c/o
Cogent Biosciences, Inc., 4840 Pearl E Circle, Suite 100,


Boulder, Colorado 80301 (US). **SMITH, Aaron Christo-
pher**; c/o Cogent Biosciences, Inc., 4840 Pearl E Circle,
Suite 100, Boulder, Colorado 80301 (US). **SCAGGS, Toya
D.**; c/o Cogent Biosciences, Inc., 4840 Pearl E Circle, Suite
100, Boulder, Colorado 80301 (US). **DAHLKE, Joshua**;
c/o Cogent Biosciences, Inc., 4840 Pearl E Circle, Suite
100, Boulder, Colorado 80301 (US). **JALLURI, Ravi Ku-
mar**; c/o Cogent Biosciences, Inc., 4840 Pearl E Circle,
Suite 100, Boulder, Colorado 80301 (US). **CHICARELLI,
Mark Joseph**; c/o Cogent Biosciences, Inc., 4840 Pearl E
Circle, Suite 100, Boulder, Colorado 80301 (US). **SALI-
TURO, Leah J.**; c/o Cogent Biosciences, Inc., 4840 Pearl E
Circle, Suite 100, Boulder, Colorado 80301 (US). **MEJIA,
Macedonio J.**; c/o Cogent Biosciences, Inc., 4840 Pearl E
Circle, Suite 100, Boulder, Colorado 80301 (US). **CHAT-
TERJEE, Payal**; c/o Cogent Biosciences, Inc., 4840 Pearl
E Circle, Suite 100, Boulder, Colorado 80301 (US).

(74) Agent: **SIEKMAN, Michael** et al.; GOODWIN PROC-
TER LLP, 100 Northern Avenue, Boston, Massachusetts
02210 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,

(54) Title: COMPOUNDS FOR FGFRS INHIBITORS



(57) Abstract: A compound having the following structure of Formula (I): (I) or a stereoisomer, salt, or tautomer thereof, wherein R^1 , R^2 , R^5 , A, B, X, and Y are as defined herein. Pharmaceutical composition comprising the compounds, and their use in methods of treating diseases are also described.

WO 2024/151638 A3

[Continued on next page]

DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:

15 August 2024 (15.08.2024)